We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+104.89%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$5.23M
Cap. Flow
-$14.9M
Cap. Flow %
-13.95%
Top 10 Hldgs %
68.17%
Holding
61
New
11
Increased
14
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$4.6M
2
ABVX
Abivax
ABVX
+$3.95M
3
JSPR icon
Jasper Therapeutics
JSPR
+$3.74M
4
ZOOZ
ZOOZ Strategy Ltd
ZOOZ
+$3.7M
5
NSPR icon
InspireMD
NSPR
+$3.01M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$10.8M
2
VRNA
Verona Pharma
VRNA
+$8.99M
3
ZVRA icon
Zevra Therapeutics
ZVRA
+$6.3M
4
ARVN icon
Arvinas
ARVN
+$3.68M
5
SCPH
scPharmaceuticals
SCPH
+$3.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$63.4M
$11M 10.36%
8,753,290
+1,766,546
+25% +$2.8M
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
$10.4M 9.75%
108,404
+8,404
+8% +$536K
TARA icon
3
Protara Therapeutics
TARA
$231M
$9.3M 8.74%
2,139,000
– –
RZLT icon
4
Rezolute
RZLT
$451M
$7.05M 6.62%
750,000
– –
PRAX icon
5
Praxis Precision Medicines
PRAX
$10.2B
$7.04M 6.61%
132,805
-16,529
-11% -$801K
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.41B
$6.66M 6.25%
175,600
+1,000
+0.6% +$21.6K
JSPR icon
7
Jasper Therapeutics
JSPR
$26.6M
$6.21M 5.83%
2,668,395
+1,234,567
+86% +$3.74M
ABVX
8
Abivax
ABVX
$11.1B
$5.47M 5.13%
+64,389
New +$3.95M
NSPR icon
9
InspireMD
NSPR
$37.5M
$5.17M 4.85%
2,143,698
+1,239,669
+137% +$3.01M
ZOOZ
10
ZOOZ Strategy Ltd
ZOOZ
$43M
$4.28M 4.02%
+100,000
New +$3.7M
ALMS
11
Alumis Inc
ALMS
$3.51B
$3.78M 3.55%
946,683
-674,163
-42% -$2.78M
LNTH icon
12
Lantheus
LNTH
$6.59B
$3.77M 3.54%
+73,545
New +$4.6M
AVTX icon
13
Avalo Therapeutics
AVTX
$1.06B
$3.35M 3.15%
263,642
+108,670
+70% +$935K
STRO icon
14
Sutro Biopharma
STRO
$423M
$2.71M 2.54%
312,000
+6,000
+2% +$51.1K
EPRX
15
Eupraxia Pharmaceuticals
EPRX
$435M
$2.08M 1.95%
+352,000
New +$1.92M
RAPT
16
DELISTED
RAPT Therapeutics
RAPT
$2.06M 1.94%
+79,977
New +$1.05M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.82B
$2M 1.88%
+130,000
New +$1.7M
TRVI icon
18
Trevi Therapeutics
TRVI
$2.54B
$1.88M 1.76%
+205,000
New +$1.54M
QURE icon
19
uniQure
QURE
$3.2B
$1.87M 1.75%
+32,000
New +$581K
VRDN icon
20
Viridian Therapeutics
VRDN
$2.61B
$1.87M 1.75%
86,500
– –
EDSA icon
21
Edesa Biotech
EDSA
$50.5M
$1.7M 1.6%
687,500
– –
TELA icon
22
TELA Bio
TELA
$41.6M
$1.11M 1.05%
747,410
– –
ELDN icon
23
Eledon Pharmaceuticals
ELDN
$284M
$899K 0.84%
346,973
+8,000
+2% +$23.4K
CRBP icon
24
Corbus Pharmaceuticals
CRBP
$177M
$772K 0.72%
61,000
+2,000
+3% +$19K
TENX icon
25
Tenax Therapeutics
TENX
$51.6M
$634K 0.6%
83,333
– –
1
2 3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return

Velan Capital Investment Management's Q3 2025 Portfolio in Review

As of Q3 2025, Velan Capital Investment Management held 61 positions worth $106M, up 5.2% from $101M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Velan Capital Investment Management withdrew a net $14.9M in Q3 2025, closing 12 positions and reducing 5 holdings. Its most notable exit was Verona Pharma, an estimated $8.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Velan Capital Investment Management opened a new position in Lantheus worth $3.77M.

  • Velan Capital Investment Management's largest Q3 2025 buy was Lantheus: 73,545 shares worth $3.77M.
  • Velan Capital Investment Management added most to Jasper Therapeutics in Q3 2025, an estimated $3.74M increase.
  • Velan Capital Investment Management's biggest Q3 2025 reduction was Tourmaline Bio, cutting an estimated $10.8M.
  • Velan Capital Investment Management fully exited Verona Pharma in Q3 2025, selling an estimated $8.99M.
  • Velan Capital Investment Management's ten largest holdings make up 68% of its $106M portfolio in Q3 2025.
  • Velan Capital Investment Management opened 11 new positions and closed 12 in Q3 2025.
  • Velan Capital Investment Management's portfolio value rose 5.2% quarter-over-quarter to $106M.

Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.